Wall Street Analysts Think Profound Medical (PROF) Could Surge 82.37%: Read This Before Placing a Bet

The consensus price target hints at an 82.4% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Dec 5, 2025

Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation

– CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target – – CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target –

GlobeNewsWire • Dec 4, 2025

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

New BPH module and clinical data reinforce the TULSA Procedure™'s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption New BPH module and clinical data reinforce the TULSA Procedure™'s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption

GlobeNewsWire • Nov 28, 2025

Profound Medical (PROF) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Profound Medical (PROF), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Investment Research • Nov 24, 2025

Profound Medical (PROF) Just Flashed Golden Cross Signal: Do You Buy?

Profound Medical (PROF) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PROF's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Zacks Investment Research • Nov 24, 2025

Wall Street Analysts Believe Profound Medical (PROF) Could Rally 97.59%: Here's is How to Trade

The consensus price target hints at a 97.6% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 19, 2025

Profound Medical (PROF) Upgraded to Buy: What Does It Mean for the Stock?

Profound Medical (PROF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Nov 19, 2025

Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease

Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy

GlobeNewsWire • Nov 18, 2025

Profound Medical Reports Strong Third Quarter 2025 Financial Results

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).

GlobeNewsWire • Nov 13, 2025

Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates

Profound Medical (PROF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.38 per share a year ago.

Zacks Investment Research • Nov 13, 2025